MGMT and Marinesco-Sjogren syndrome: In particular, the phase II Maya study evaluated the combination of temozolomide priming followed by a combination of low-dose ipilimumab and nivolumab in patients with MSS and O6-methylguanine-DNA methyltransferase (MGMT)-silenced mCRC.